Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAG + Imatinib in Refractory/Relapsed AML
NCT00594555Phase 2Withdrawn
- Sponsor
- University of Cincinnati
- Start
- Nov 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), sponsored by University of Cincinnati. Planned start Nov 2007; status: withdrawn.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00594555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594555.